Major histocompatibility complex class I (MHC-I
HLA-I molecules serve as a vital component of cellular immunity by presenting endogenous peptide epitopes on the cell surface for scrutiny by CD8 + T cells and NK cells. These peptides are derived from intracellular proteins that have been proteolytically degraded, and during the course of a viral infection they will include epitopes originating from the invading pathogen. HLA-I molecules bind compatible peptides via a specialized groove capped by a conserved network of residues that form hydrogen bonds with the N termini (P1) and C termini (PΩ) of the peptide 1 . The peptide is further anchored at specific pockets spaced along the groove; for many HLA allotypes this anchoring typically occurs at the P2 and PΩ positions [2] [3] [4] [5] . The nature of these 'anchoring pockets' differs between HLA-I molecules, and thus defines their unique peptide repertoires 5 .
The closed-end nature of the HLA-I antigen-binding cleft generally constrains the repertoire of peptides to 9−11 amino acids in length. Some longer HLA-I-restricted peptides have been described, but because of the conserved polar interaction network with the N and C termini in the P1 and PΩ pockets, longer peptides are canonically accommodated in the groove only after they adopt a 'bulged' conformation in which the central portion of the peptide epitope projects from the groove 6, 7 . The T cell receptor (TCR) binds these bulged regions of the peptide while simultaneously contacting the HLA-I molecule. Although the KIR family of receptors on NK cells demonstrate broader peptide recognition than TCRs, they also bind HLA in a peptide-dependent manner [8] [9] [10] . Particularly important are residues at positions PΩ-1 and PΩ-2 that often directly contact the KIR 11, 12 . Isolated reports have described peptides that protrude at the C terminus from the peptide-binding groove, with the PΩ-1 residue acting as an alternate C-terminal anchor, although the extent to which this represents a common occurrence remains unclear [13] [14] [15] . Such noncanonical HLA-I-peptide landscapes are important because they potentially form unique contact surfaces for TCR and KIR recognition, with attendant implications for disease-relevant immune responses 14, 16, 17 . In contrast, it is not known whether peptides can protrude from the N terminus of the HLA-I antigen-binding cleft.
The HLA-B*57:01 allele is associated with delayed disease progression in HIV-1-infected individuals [18] [19] [20] [21] and hypersensitivity to the antiviral drug abacavir [22] [23] [24] . In HLA-B*57:01 + HIV-1-infected individuals, robust CD8 + T cell responses specific for four epitopes within the p24 Gag protein (TW10, IW9, QW9 and KF11) are associated with such protective immunity 19, [25] [26] [27] . Cellular immune responses against these epitopes drive the selection of amino acid mutations that allow viral escape from the immune system [28] [29] [30] . A common escape mutation in the p24 Gag epitope TW10 (TSTLQEQIGW; residues 240-249) is Thr242Asn, which lies at P3 of the epitope (T3N) [31] [32] [33] . The emergence a r t i c l e s of this variant coincides with loss of the original CD8 + T cell response in many patients 27, 32 and with impaired viremic control, especially after the acquisition of compensatory mutations 30, 34 . In addition to acting as a restriction element for CD8 + T cell responses, HLA-B*57:01 is also a potent ligand for KIR3DL1, which regulates NK cell function. Furthermore, genetic association studies have implicated the interaction between HLA-B*57 and certain allelic variants of KIR3DL1 with delayed progression to AIDS [35] [36] [37] .
Here we show that the repertoire of endogenous and viral peptides presented by HLA-B*57:01 contains sets of both N-and C-terminally extended epitopes. We identified a characteristic motif as a signature of N-terminally extended peptides, and our structural studies revealed a noncanonical binding mode whereby the N-terminal residue overhangs the peptide-binding groove of HLA-B*57:01. This novel mode of peptide binding enables HIV-1 to escape immune recognition via a register shift within the TW10 epitope that alters the presented antigenic structure upon mutation to T3N. In addition to its consequences for the adaptive immune response, this mutation also had an effect on KIR3DL1 recognition, which highlights the differences and 'molecular tension' in the adaptive and innate immune systems' recognition of this common HIV-1 epitope.
RESULTS

Structure of HLA-B*57:01-TW10 in complex with KIR3DL1
To extend our previous analysis of KIR3DL1 bound to selfpeptide-presenting HLA-B*57:01 (ref. 12), we determined the crystal structure of KIR3DL1*001-HLA-B*57:01 in complex with the HIV-1 p24 Gag epitope TW10 (TSTLQEQIGW; residues 240-249) ( Table 1) .
The mode of KIR3DL1 recognition of the viral epitope was essentially identical to that of the self-peptide bound to HLA-B*57:01 (ref. 12) (Fig. 1a) . The three KIR3DL1 domains engaged HLA-B*57:01 in a conserved orientation, with the D0 domain docking at the side and the D1 and D2 domains docking at the C-terminal end of the peptide binding cleft, above the α1 and α2 helices, respectively (Fig. 1a) . The D1 domain interacted with the Bw4 motif on the α1 helix. In the course of our analysis, we noted that the TW10 epitope adopted a unique conformation not previously observed for HLA-I-peptide complexes. Namely, the N-terminal region of the TW10 epitope protruded from the antigen-binding cleft and thus did not occupy the A pocket (Fig. 1b) . Instead, the second and third residues of the TW10 epitope were located in the A and B pockets, respectively (Fig. 1b) .
Comparison with available HLA-B*57:01-peptide structures 12, 23, 38 showed that, with the exception of a 0.7-Å shift of Trp167 (not shown), there were minimal structural distortions to the peptide-binding cleft that accompanied this previously unobserved peptide conformation (r.m.s. deviation < 0.25 Å over Cα positions 1-180). Because of the closed nature of the peptide-binding groove, the P-1 residue (one residue N-terminal of P1) of the peptide projected at a right angle from the plane of the floor of the groove, with the side chain pointing back along the length of the peptide (Fig. 1c) . Contacts between P-1-Thr and HLA-B*57:01 were limited to water-mediated H-bonds between Trp167 and the P-1-Thr peptide backbone, and van der Waals interactions between Glu63 and Leu163 and the P-1-Thr side chain (Fig. 1c) . Contacts between P-1-Thr and the rest of the peptide included watermediated H-bonds with P2-Thr and P4-Gln (Fig. 1c) .
The A pocket is characterized by a highly conserved set of residues including Tyr7 and Tyr171 that contribute a network of H-bonds, a r t i c l e s thus stabilizing the N terminus of the presented peptide. In the HLA-B*57:01-TW10 complex, the P1-Ser residue of the TW10 epitope occupied the A pocket of HLA-B*57:01 and thus maintained a network of H-bonds with Tyr7 and Tyr171 (Fig. 1d) . As a result, the P1-Ser side chain was rotated approximately 180° from the canonical positioning of a P1 anchored residue. Accordingly, the slippage of TW10 from the groove of HLA-B*57:01 was accompanied by distortion of the peptide at the P1 residue and not by structural distortion of the peptide-binding groove. As peptide repertoire data for HLA-B*57:01 had previously demonstrated the P2 anchor preference for Ser or Thr 23 , it was conceivable that either P2-Ser or P3-Thr could act as an N-terminal anchor for TW10. However, the high-resolution structure of HLA-B*57:01-TW10 showed unambiguous electron density across the peptide, thus indicating that only one conformation of TW10 was present in the crystal lattice. Further, we confirmed by the use of hydrogen-deuterium exchange with mass spectrometry that, in contrast to the peptide free in solution, TW10 adopts a single conformation while in complex with B*57:01 ( Supplementary  Fig. 1 ). Thus, the P-1-P2 residues enable the peptide to extend from the peptide-binding cleft of HLA-B*57:01.
N-terminal extensions within the HLA-B*57:01 immunopeptidome
To determine whether N-terminally extended peptides are a general feature of the HLA-B*57:01 restricted immunopeptidome, we sought to define the range of self-peptides and HIV-Gag epitopes presented by HLA-B*57:01. We isolated peptides from C1R cells transfected with expression constructs for HLA-B*57:01 and HIV-1-Gag and sequenced them using tandem mass spectrometry. The resulting data set was Table 1 ). As described previously 23 , HLA-B*57:01 ligands were predominantly 9-11 amino acids in length and showed enrichment of S/T/A at the P2 anchor, and aromatic residues at the C terminus (Fig. 2) . In addition, a thorough bioinformatic interrogation of this expanded HLA-B57 peptidome revealed a number of peptides that contained these shorter peptides (9-11 amino acids) with an N-terminal extension and were isolated from both HIV-1-Gag + and HIV-1-Gag − cells. Extended sets of peptides were defined on the basis of the following criteria: (i) minimal core sequence of 7-11 amino acids and (ii) maximal sequence of >9 amino acids. A total of 1,275 sets of peptides met these criteria; among these, 17%, 18% and 12% of 9-, 10-and 11-residue peptides possessed only N-terminal extensions, whereas far fewer were purely C-terminally extended (3%, 3% and 2%, respectively) ( Fig. 2a) . To define the sequence features that were predisposed to N-terminal extensions, we aligned peptides exhibiting N-terminal heterogeneity on the basis of their minimal-sequence P1 (Supplementary Table 2 ). We visualized the motif as a sequence logo encompassing P-1 to P3 with iceLogo 39 . We also generated a similar motif from P1 to P3 of all 9-11 residue peptides within the HLA-B*57:01 peptide data set and aligned them at P1 for comparison (Fig. 2b,c) . Whereas the global HLA-B*57:01 9-11-amino-acid peptide motif showed enrichment of Lys, Ile and Arg at P1, the N-terminally extended peptides were enriched for Ser, Thr and Ala at P1 and P-1. Given that Ser, Thr and Ala are preferred P2 anchors for HLA-B*57:01, these residues could potentially be acting as alternative anchor sites in longer peptides, thus resulting in bulged conformations within the peptide-binding groove. However, given the appearance of numerous sets in which a minimal core sequence was found with several extension lengths a r t i c l e s (for example, set 233: STTSVASSW, TSTTSVASSW, DTSTTSVASSW, HDTSTTSVASSW, SHDTSTTSVASSW, SSHDTSTTSVASSW and TASSHDTSTTSVASSW), not all of which contained Ser, Thr or Ala at the second residue, it seemed likely that the excess residues might overhang the cleft. Thus, we defined the N-terminal protrusion motif as Ser/Thr/Ala at P-1 to P2.
TW10 is part of an extended set restricted by HLA-B*57:01
Of the 11,954 peptides used in this analysis, 9 were derived from the Gag polypeptide. Among the Gag-derived epitopes, we observed two N-terminally extended epitope sets: QW9 and TW10 (set 33 and set 500; Fig. 3a and Supplementary Table 2) . The TW10 epitope was the minimal peptide observed within its N-terminally extended set that contained multiple extension lengths (Fig. 3a) . To determine the relative abundance of each peptide in the set, we measured the extracted ion chromatogram specific for each of the peptides (Fig. 3b) . The N-terminally extended AGTTSTLQEQIGW peptide was the most intense ion and by inference the most abundant, followed by TTSTLQEQIGW, GTTSTLQEQIGW and TW10 (Fig. 3b) . We also identified two longer N-terminally extended peptides (DIAGTTSTLQEQIGW and SDIAGTTSTLQEQIGW), at significantly lower levels (Fig. 3b) . Taken together, our data suggest that a common motif characterizes N-terminally protruding HLA-B*57:01-restricted peptides regardless of origin (i.e., self or viral).
Structure of HLA-B*57:01 presenting extended self-peptides
To further probe the structural nature of the N-terminal extension motif, we investigated three epitopes from the self-repertoire of HLA-B*57:01. We selected the peptides TSTTSVASSW (UniProt Q14679), TSTFEDVKILAF (UniProt Q6YHU6) and SSTRGISQLW (UniProt Q96HA1), each of which formed part of a nested set (set 233, set 926 and set 736, respectively; Supplementary Table 2) . Crystals of the refolded HLA-B*57:01-peptide complexes formed in the space group P2 1 2 1 2 1 with unit cell dimensions of ~a = 50, b = 82 and c = 110 Å, and diffracted to high resolution ( Table 1) .
All of these HLA-B*57:01-peptide complexes adopted the noncanonical conformation observed for HLA-B*57:01-TW10. Namely, the Ser residue in the second position of the TSTFEDVKILAF (Fig. 4a) , TSTTSVASSW and SSTRGISQLW peptides occupied the A pocket, which normally accommodates the N-terminal amide. As these selfpeptide complexes were highly similar, we restricted analysis to the HLA-B*57:01-TSTFEDVKILAF structure. The water-mediated H-bonding network to the Thr at position P-1 to residues Asn66 and Trp167 of HLA-B*57:01 was highly conserved (Figs. 1c and 4b) . Similarly, the Hbonding network at the N terminus of the peptide-binding groove was also conserved, with the hydroxyl of P1-Ser maintaining the contacting Tyr7, Tyr59, Glu63 and Tyr171 (Figs. 1d and 4c,d) . Accordingly, the P-1-to-P2 motif identified in the repertoire analysis is a common motif that enables the peptide to protrude from the N terminus of HLA-B*57:01.
The structural basis of viral escape via the T3N mutation
The TW10 epitope undergoes a common and rapid substitution at the N terminus, namely, T3N (TSNLQEQIGW), to facilitate HIV-1 immune escape in HLA-B*57:01 + individuals. To address this phenomenon at the molecular level, we determined the crystal structure of HLA-B*57:01 in complex with the T3N peptide and KIR3DL1 (Table 1) . Overall, the contacts between KIR3DL1 and HLA-B*57:01 were conserved between the TW10 and T3N structures. However, contacts between KIR3DL1 and the HLA-bound peptide were markedly different for TW10 and T3N. KIR3DL1 formed two contacts with the T3N peptide. The D1 Gly116 bound P7-Gln, whereas Tyr200 at the D1/D2 hinge loop bound a r t i c l e s P8-Ile (Fig. 5a) . In contrast, KIR3DL1 did not directly contact the TW10 peptide. Instead, water-mediated contacts were formed between Tyr200 and the backbones of P8-Gly and P9-Trp (Fig. 5b) . KIR3DL1 therefore interacted differently with TW10 and T3N as a result of changes in the bound peptide conformation (detailed below).
The Thr3Asn substitution caused the peptide to adopt a conventional anchoring mode in which it bound to HLA-B*57:01 with the A and B pockets occupied by the Thr and Ser in the first two peptide positions, respectively (Fig. 5c) . Notably, the HLA-B*57:01-TW10 complex was more stable than the HLA-B*57:01-T3N complex, with a melting temperature of 61.8 °C, compared with 55.0 °C in circular dichroism assays (Supplementary Fig. 2) . The inability of Asn3 to occupy the B pocket is consistent with a previous HLA-B*57:01 peptide-elution study in which Asn was not observed as an anchor residue at P2 (ref. 23 ). The change in anchoring at P2 shifted the peptide register across all positions except the C-terminal anchor and P9-Gly (Fig. 5d) . Accordingly, the secondary anchor positions also differed between TW10 and T3N. Specifically, the TW10 secondary anchors at P3-Leu, P6-Gln and P7-Ile were reassigned to P3-Asn, P5-Gln and P6-Glu, respectively, in T3N. Consequently, the P-1-Thr, P4-Gln and P5-Glu side chains were considerably solvent exposed in TW10, whereas P4-Leu, P5-Gln and P8-Ile were considerably solvent exposed in T3N (Fig. 5d) . Thus, the Thr3Asn mutation shifts the peptide register within the peptide-binding groove, thereby resulting in the presentation of an altered peptide conformation to immune cell receptors.
Escape mutants in TW10 attenuate KIR3DL1 recognition
To determine whether the T3N escape mutation affects binding to KIR3DL1, we used surface plasmon resonance to measure the affinity of KIR3DL1*001 for HLA-B*57:01-TW10 and HLA-B*57:01-T3N.
The TW10 complex bound more strongly to KIR3DL1 (K D ~ 60 µM) than the T3N complex did (K D ~ 100 µM) (Fig. 6a) . We then used fluorochrome-labeled tetrameric forms of HLA-B*5701-TW10 and HLA-B*5701-T3N to stain HEK293T cells transfected with prevalent KIR3DL1 allotypes (*001, *005 and *015) (portions of the data for TW10 have been published previously 40 ). The T3N mutation almost entirely abrogated HLA-B*57:01 tetramer binding to all three surfaceexpressed allotypic variants of KIR3DL1 (Fig. 6b) . However, we did observe some differences between allotypes, and found KIR3DL1*015 to be the most sensitive to changes in the epitope.
We probed the relative contribution of specific KIR3DL1*001 residues to the HLA-B*57:01-TW10 and HLA-B*57:01-T3N interfaces further by mutational analysis. Overall, there were distinct differences in the recognition of these HLA-B*57:01-peptide complexes (Fig. 6c,d) . Starting with the D0 domain, the T3N complex was less sensitive than the TW10 complex to substitution at Phe9, but more sensitive to substitution at Phe34 (Fig. 6c,d ). In the D1 domain, substitutions at Gly138 and Ser140 dramatically altered recognition of the TW10 complex yet had a minimal effect on recognition of the T3N complex, whereas the Leu166Ala mutation was sufficient to restore T3N binding to wild-type (TW10) levels (Fig. 6c,d) . Substitutions across the D2 domain indicated similar contributions from Tyr200, Glu201, Ser227, Ser228, Phe276, His278 and Ser279. In contrast, the Arg277Ala substitution abrogated binding to the T3N complex while improving recognition of the TW10 complex.
Taken together, these findings demonstrate that the viral escape mutant T3N attenuates KIR3DL1 recognition in an allotype-dependent manner. Furthermore, the KIR3DL1 residue Leu166, which sat proximal to the interface with the peptide in the ternary structure, has a central role in this effect. The altered peptide conformation of T3N therefore limits In contrast, the N-and C-terminal pockets of HLA-I molecules are closed, which restricts the bound peptides to a typical length of 9-11 amino acids. Nevertheless, longer MHC-I-restricted epitopes have been described that adopt a centrally bulged conformation while maintaining the N-and C-terminal anchor residues. In addition, there have been isolated reports of peptides with residues overhanging the C-terminal pocket of HLA-A*02:01 (refs. 13, 14) and H2-M3 (ref. 41) . It has been proposed that N-terminally extended peptides could be presented 42, 43 , yet whether such peptides could overhang the more buried N-terminal pocket or whether they are centrally bulged remained unclear. Our comprehensive analysis of the repertoire of peptides naturally presented by HLA-B*57:01 shows that approximately 27% are clustered into extended sets, most of which are solely N-terminally extended (20%), whereas the others are either C-terminally extended or both N-and C-terminally extended. We have also shown that N-terminally extended peptides are accommodated via protrusion from the groove. From the amino acid enrichment data for N-terminally extended HLA-B*57:01 epitopes and our structure-based insights, we can devise the following rules that predict the P-1 overhang: (i) the peptide should be at least one residue longer than the minimal epitope length that can be presented, (ii) the P2 residue should be a residue that favors binding in the B pocket and (iii) the P1 residue should be smaller than leucine to enable a 180° rotation within the A pocket. Notably, none of these criteria are specific to HLA-B*57:01, and thus we speculate that N-terminally protruded peptides will be a common feature of immunopeptidomes. Accordingly, we define a new mechanism that allows MHC-I molecules to present lengthy epitopes.
Viruses have developed numerous strategies to evade HLA-mediated immune detection, including mechanisms that directly interfere with the presentation of viral epitopes and HLA molecules on the cell surface 44, 45 . For example, HIV-1 can increase cellular endocytosis of HLA molecules via nef 46 , limit HLA transcription and peptide processing via tat 47 , and suppress TAP-mediated peptide transport into the endoplasmic reticulum 48 . Under selection pressure from the immune system, HIV-1 also mutates rapidly to evade cytotoxic T lymphocyte responses. These epitope-centric escape mutations typically alter the conformation of exposed residues that interact with the TCR [49] [50] [51] or abrogate peptide presentation via effects on antigen processing or HLA-I binding 52, 53 . Here we report a novel mode of escape whereby the common T3N mutant exploits the P-1 overhang of TW10 and the anchor-residue preferences in the A and B pockets to shift the register of the peptide within HLA-B*57:01. This structural rearrangement alters the conformation of exposed peptide residues to enable immune escape [31] [32] [33] 54 .
There has been considerable interest in the idea that KIR-dependent recognition of HLA-I can shape the nature of viral escape mutations, with some studies suggesting that inhibitory receptors expressed by NK cells may exert some selective pressure during HIV infection 55, 56 . Although immune recognition and the subsequent immune escape observed for the TW10 epitope is likely to be a predominantly T-cell-mediated phenomenon, it is plausible that this epitope also affects NK cell recognition. a r t i c l e s Such effects would be accentuated by the viral modulation of the peptide repertoire through the inclusion of viral peptides, which have been observed to constitute up to 50% of the immunopeptidome in the early stages of vaccinia infection 57 , and alterations to self-peptide presentation. However, it is unclear whether the T3N escape variant actually affects NK cell inhibition via engagement of KIR3DL1. A previous study using surface plasmon resonance reported reduced interaction with T3N presented by HLA-B*57:03 (ref. 33) . In contrast, another study based on tetramer staining of KIR3DL1-transfected cell lines reported no interaction 58 . Although this discrepancy is probably a result of the different experimental approaches, it is clear from our structural, surface plasmon resonance and tetramer-staining data that KIR3DL1 recognizes T3N, albeit with lower affinity than for TW10 in the context of HLA-B*57:01.
There are also well-described C-terminal escape mutations within the TW10 epitope, such as G9D, that abrogate KIR3DL1 recognition 40 . Notably, these effects are KIR3DL1-allotype-dependent, in agreement with the findings of a recent study 59 . This is in line with recent reports that demonstrated allotypic variation in the capacity of KIR3DL1 to bind defined HLA-I-peptide complexes 40, 59 . Accordingly, there appears to be a 'molecular tension' between the inhibitory germline-encoded and activating rearranging receptors of the innate and adaptive arms of the immune system as they converge to target a common HIV-1 determinant and its escape variants presented by HLA-B*57:01. In summary, our structural and proteomics analyses reveal a novel mechanism of viral immune escape whereby HIV-1 mutates to exploit a previously undescribed mode of peptide presentation by MHC-I.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 100 K. Data sets were collected at the MX2 beamline (Australian Synchrotron, Clayton, Victoria, Australia). The data were recorded on a Quantum-315 CCD (charge-coupled device) detector and were integrated and scaled using MOSFLM and SCALA from the CCP4 program suite [65] [66] [67] . Details of the data processing statistics are summarized in Table 1 . The crystal structures were solved by molecular replacement, as implemented in PHASER 68 , with HLA-B*57:01-LF9 used as the search model (PDB 2RFX). Refinement of the models proceeded with iterative rounds of manual building in COOT 69 and refinement in PHENIX 70 . The structures were validated with MOLPROBITY 71 . Refinement statistics are summarized in Table 1 .
Surface plasmon resonance. Surface plasmon resonance experiments were conducted at 298 K on a Biacore 3000 instrument using HBS buffer (10 mM HEPES-HCl, pH 7.4, 150 mM NaCl and 0.005% surfactant P20). The W6/32 antibody was immobilized on a CM5 chip via amine coupling to capture HLA-peptide complexes, creating a surface density of approximately 700 response units (RU). KIR3DL1*001 (2.37-300 µM) was injected over the chip at a flow rate of 5 µL/min. The response to W6/32 alone was subtracted from the response to KIR3DL1*001-HLA-B*5701-peptide. Equilibrium data were analyzed with GraphPad Prism. Data in the main text are representative of two independent experiments. Equilibrium binding constants were generated with nonlinear regression analysis using the following equation: Y = B max X/(K d + X), where B max is the extrapolated binding at saturation.
Transfection studies. FLAG-tagged KIR3DL1*001 was cloned into the pEF6 vector. Specific nucleotide residues were mutated with the QuikChange II sitedirected mutagenesis kit (Stratagene), and constructs were introduced into HEK293T cells with FuGene 6 Transfection Reagent (Roche). After 48 h, the cells were harvested and stained with anti-Flag (clone M2, Sigma-Aldrich) or tetramer for 30 min at 4 °C. The cells were then washed and analyzed on a Fortessa flow cytometer (BD Biosciences). Staining with anti-Flag showed that none of the introduced mutations substantially affected cell surface expression of KIR3DL1*001 (data not shown). KIR3DL1 mutant data in the main text are representative of three independent experiments. KIR3DL1 allotype data in the main text are representative of four independent experiments; data were not analyzed if Flag expression was present on >5% of cells, which resulted in a minimum of two replicates in this assay. HEK293T cells were regularly tested and maintained as mycoplasma free for the duration of these studies. Tables 1-3 . Other data from this study are available from the corresponding authors upon reasonable request.
